Brick & Kyle Associates’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Brick & Kyle Associates’s Portfolio GNMX Stock Details GNMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-1,000	Closed	-$2K	–	394
2017 Q1	$2K	Hold	1,000	–	–	﹤0.01%	409
2016 Q4	$5K	Hold	1,000	–	–	﹤0.01%	383
2016 Q3	$6K	Hold	1,000	–	–	﹤0.01%	376
2016 Q2	$6K	Hold	1,000	–	–	﹤0.01%	384
2016 Q1	$4K	Hold	1,000	–	–	﹤0.01%	393
2015 Q4	$6K	Hold	1,000	–	–	0.01%	370
2015 Q3	$8K	Hold	1,000	–	–	0.01%	367
2015 Q2	$6K	Hold	1,000	–	–	0.01%	408
2015 Q1	$8K	Hold	1,000	–	–	0.01%	395
2014 Q4	$5K	Buy	+1,000	New	+$4.94K	﹤0.01%	396

Other funds holding GNMX

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

ECM

Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Brick & Kyle Associates's GNMX Position: Q2 2017 in Review

Brick & Kyle Associates sold out of Aevi Genomic Medicine Inc (GNMX) in Q2 2017, closing a stake of 1,000 shares — an estimated $2K sold.

Brick & Kyle Associates first reported a position in GNMX in Q4 2014 and held it in 10 quarters. The position peaked at $8K in Q3 2015. 51 funds tracked by Wall St. Rank hold GNMX as of Q2 2017.

Brick & Kyle Associates reported no remaining Aevi Genomic Medicine Inc position as of Q2 2017 after selling out during the quarter.
Brick & Kyle Associates sold 1,000 Aevi Genomic Medicine Inc shares in Q2 2017, an estimated $2K.
Brick & Kyle Associates first reported a position in Aevi Genomic Medicine Inc in Q4 2014 and held it in 10 quarters.
Brick & Kyle Associates's Aevi Genomic Medicine Inc position peaked at $8K in Q3 2015.
51 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q2 2017.

Based on Brick & Kyle Associates's 13F filing for Q2 2017, filed 14 Aug 2017.